The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma

Abstract Purpose Accurate assessment of residual disease of tumor and lymph nodes after neoadjuvant immunochemotherapy is crucial in the active surveillance for patients with pathological complete response (pCR) and the optimal extent of lymphadenectomy for patients with non-pCR. This post-hoc analysis aimed to evaluate the performance of 18 F-FDG PET/CT to predict the pathological response to neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma (ESCC). Methods Fifty-eight resectable ESCC patients, received two cycles of camrelizumab in combination with chemotherapy were enrolled in the final analysis. The 18 F-FDG PET/CT scans were acquired at baseline (scan-1) and after immunochemotherapy but prior to surgery (scan-2). Maximum standardized uptake value (SUV max ), mean standardized uptake value (SUV mean ), tumor-to-blood pool SUV max ratio (SUV TBR ), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were evaluated for their association with the pathological response to immunochemotherapy. Results Nineteen patients (32.8%, 19/58) had pCR and thirty-nine patients (67.2%, 39/58) had non-pCR after two doses of camrelizumab and chemotherapy. At scan-2, the SUV max , SUV mean , SUV TBR , TLG and MTV were significantly lower in pCR than that in non-pCR patients. Decrease in TLG and MTV between scan-2 and scan-1 of the same patient were significantly higher in the pCR than in the non-pCR group. In the receiver operating characteristic curve analysis, SUV max , SUV mean , SUV TBR , TLG and MTV in scan-2 showed excellent predictive value for the pCR of primary tumors. Furthermore, SUV max in scan-2 were higher in positive lymph nodes than that in negative ones, suggesting a high negative predictive ability (98.6%) with a cut-off value at 1.4. Conclusion The parameters of 18 F-FDG PET/CT have the excellent performance for predicting pCR after the combined neoadjuvant immunochemotherapy in resectable ESCC. Trial registration : ChiCTR ChiCTR2000028900. Registered 6 January 2020.